Login to Your Account



Clinic Roundup


Monday, January 14, 2013

• Mesoblast Ltd., of Melbourne, Australia, said its Phase II trial for lumbar spinal fusion met its safety and efficacy endpoints, with results suggesting that NeoFuse, its product comprising allogeneic mesenchymal precursor cells (MPCs), is as effective for interbody lumbar fusion as bone autograft without the need for a second surgical procedure and its attendant morbidity risks.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription